These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20518075)

  • 61. Short-term chlorambucil for refractory uveitis in Behcet's disease.
    Mudun BA; Ergen A; Ipcioglu SU; Burumcek EY; Durlu Y; Arslan MO
    Ocul Immunol Inflamm; 2001 Dec; 9(4):219-29. PubMed ID: 11935432
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The use of interferon alpha in Behçet disease: review of the literature.
    Kötter I; Günaydin I; Zierhut M; Stübiger N
    Semin Arthritis Rheum; 2004 Apr; 33(5):320-35. PubMed ID: 15079763
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement?
    Akman-Demir G; Ayranci O; Kurtuncu M; Vanli EN; Mutlu M; Tugal-Tutkun I
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S84-90. PubMed ID: 19026121
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multifocal ERG changes in patients with ocular Behçet's disease during therapy with interferon alpha 2a.
    Stübiger N; Besch D; Deuter CM; Zierhut M; Kötter I
    Adv Exp Med Biol; 2003; 528():529-32. PubMed ID: 12918757
    [No Abstract]   [Full Text] [Related]  

  • 65. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease.
    Kaburaki T; Araki F; Takamoto M; Okinaga K; Yoshida A; Numaga J; Fujino Y; Kawashima H
    Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):709-14. PubMed ID: 19997745
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Behcet's disease with uveitis in Taiwan.
    Chung YM; Lin YC; Tsai CC; Huang DF
    J Chin Med Assoc; 2008 Oct; 71(10):509-16. PubMed ID: 18955185
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Short term cyclosporin A treatment of Behçet's disease.
    Müftüoğlu AU; Pazarli H; Yurdakul S; Yazici H; Ulkü BY; Tüzün Y; Serdaroğlu S; Altuğ E; Bahçecioğlu H; Güngen G
    Br J Ophthalmol; 1987 May; 71(5):387-90. PubMed ID: 3580358
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Ocular manifestations of Behçet's disease].
    Saadoun D; Cassoux N; Wechsler B; Boutin D; Terrada C; Lehoang P; Bodaghi B; Cacoub P
    Rev Med Interne; 2010 Aug; 31(8):545-50. PubMed ID: 20413190
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Clinical aspects of Behçet's disease--epidemiological features and visual prognosis].
    Ando K; Fujino Y; Hijikata K; Izawa Y; Masuda K
    Nippon Ganka Gakkai Zasshi; 1997 Oct; 101(10):814-8. PubMed ID: 9369064
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pityriasis rosea in a patient with Behçet's disease treated with interferon alpha 2A.
    Durusoy C; Alpsoy E; Yilmaz E
    J Dermatol; 1999 Apr; 26(4):225-8. PubMed ID: 10343467
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease.
    Krause L; Turnbull JR; Torun N; Pleyer U; Zouboulis CC; Foerster MH
    Adv Exp Med Biol; 2003; 528():511-9. PubMed ID: 12918754
    [No Abstract]   [Full Text] [Related]  

  • 72. Interferon alpha for ocular Behçet's disease.
    Pivetti-Pezzi P; Accorinti M; Pirraglia MP; Priori R; Valesini G
    Acta Ophthalmol Scand; 1997 Dec; 75(6):720-2. PubMed ID: 9527339
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement.
    Takeuchi M; Hokama H; Tsukahara R; Kezuka T; Goto H; Sakai J; Usui M
    Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1147-52. PubMed ID: 15983811
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reactivation of Behçet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen.
    Strohal R; Tschachler E; Breyer S; Uthman A; Simonitsch I; Tratting S; Scheithauer W; Stingl G; Kornek GV
    Br J Haematol; 1998 Dec; 103(3):788-90. PubMed ID: 9858232
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Preclinical and clinical study of FK506 in uveitis.
    Mochizuki M; Ikeda E; Shirao M; Fujito S; Yoshimura K; Shimada N
    Curr Eye Res; 1992; 11 Suppl():87-95. PubMed ID: 1385045
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epidemiological features and visual prognosis of Behçet's disease.
    Ando K; Fujino Y; Hijikata K; Izawa Y; Masuda K
    Jpn J Ophthalmol; 1999; 43(4):312-7. PubMed ID: 10482479
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interferon therapy for Behçet's disease.
    Alpsoy E; Yilmaz E; Başaran E
    J Am Acad Dermatol; 1994 Oct; 31(4):617-9. PubMed ID: 8089288
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Systemic interferon alpha 2b treatment in Behçet's syndrome.
    Hamuryudan V; Moral F; Yurdakul S; Mat C; Tüzün Y; Ozyazgan Y; Direskeneli H; Akoglu T; Yazici H
    J Rheumatol; 1994 Jun; 21(6):1098-100. PubMed ID: 7932420
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease.
    O'Duffy JD; Robertson DM; Goldstein NP
    Am J Med; 1984 Jan; 76(1):75-84. PubMed ID: 6691363
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy.
    Pacor ML; Biasi D; Lunardi C; Cortina P; Caramaschi P; Girelli D; Botto M; Urbani G; Lombardo G; Bambara LM
    Clin Rheumatol; 1994 Jun; 13(2):224-7. PubMed ID: 8088063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.